Abstract:

Since its outbreak in late 2019, Coronavirus Disease 2019 (COVID-19) has been ravaging the health system of most countries of the world. Although many preventive and treatment strategies have been proposed and implemented to combat the disease, these efforts seem to be insufficient, and in some cases ineffective. This is evident by the daily rising global incidence and case fatality of the COVID-19 pandemic. A situation if not mitigated early will likely crumble the global economy and tilt the world to an unprecedented global recession. This challenge demands that researchers and clinicians ask more in-depth questions about the novel coronavirus disease. Aside from age that has been confirmed to be linearly associated, what are the other possible socio-demographic and lifestyle-related risk factors that may be associated with COVID-19? What are the possible factors or comorbid conditions that may worsen clinical progression and determine the clinical outcome in confirmed COVID-19 cases? Does the pre-, peri-, or post-morbid lifestyle choices of people have an impact on COVID-19 preventive and treatment efforts? And how can we use the knowledge of the associated risk factors, comorbid conditions, and lifestyle choices of people to improve preventive efforts and clinical management of COVID-19? Answer to these questions may likely serve as an important guide for policymakers and clinicians in their design and implementation of COVID-19 targeted preventive and treatment policies and programs, especially in Low- and Middle-Income Countries (LMICs). The purpose of this article is to critically review available literature and provide evidence-based recommendations.

References:

[1] Beeching N.J., Fletcher T.E., and Fowler R., 2020, BMJ Best Practice: Coronavirus disease 2019 (COVID-19 leaflet), BMJ Publishing Group Ltd 2020, Date of access: 4/7/2020. http://patchsa.org/wp-content/uploads/2020/03/BMJ-Best-Practice-COVID-19.pdf.

[2] Bonyan F.A., Shareef L.G., Al-waily A., Abdulrazaq A.A., and Al-Rubayee W.A., 2020, COVID-19 clinical characteristics and outcomes in 60 hospitalized Iraqi patients - Case series. Medical Science, 24(104), 2251-2258.

[3] Chowdhury A.T.M.M, Karim M. R., Mehedi H.M.H, Shahbaz M., Chowdhury M.W., Dan G., et al., 2020, Analysis of the primary presenting symptoms and hematological findings of COVID19 patients in Bangladesh, ResearchGate 2020. DOI: 10.13140/RG.2.2.22406.80969.

[4] Nigeria Centre for Disease Control, 2020, National interim guidelines for clinical management of COVID-19, NCDC 2020, Date of access: 14/10/2020. https://reliefweb.int/sites/reliefweb.int/files/resources/national_covid19_case_management_guide_ncdc.pdf.

[5] World Health Organisation, 2020, WHO Coronavirus Disease (COVID-19) Dashboard, Date of access: 14/10/2020. https://covid19.who.int/.

[6] Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A., et al., 2020, COVID-19 and Cardiovascular Disease, Circulation, 141: 1648 – 1655,

 DOI: 10.1161/CIRCULATIONAHA.120.046941.

[7] Pan H., Peto R., Karim Q.A., Alejandria M., Henao-Restrepo A.M., García C.H., et al., 2020, Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results: WHO Solidarity trial consortium, WHO 2020, Date of access: 18/10/2020. https://doi.org/10.1101/2020.10.15.20209817.

[8] Khunti K., Singh A.K., Pareek M., and Hanif W., 2020, Is ethnicity linked to incidence or outcomes of covid-19? Preliminary signals must be explored urgently, BMJ, 369: 1 – 2. DOI: 10.1136/bmj.m1548.

[9] Ambrosino I., Barbagelata E., Ortona E., Ruggieri A., Massiah G., Giannico O.V., et al., 2020, Gender differences in patients with COVID-19: a narrative review, Monaldi Archives for Chest Disease, 90 (1389): 318 – 324.

[10] Mo P., Xing Y., Xiao Y., Deng L., Zhao Q., Wang H., et al., 2020. Characteristics of refractory COVID-19 pneumonia in Wuhan, China. Infectious Diseases Society of America, 2020, Oxford University Press, Date of access: 9/10/2020. https://watermark.silverchair.com/ciaa270.pdf?token=.

[11] Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., and Davidson K.W., 2020, Presenting Characteristics, Comorbidities, and Outcomes Among 5, 700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA, 323(20): 2052 – 2059. DOI:10.1001/jama.2020.6775.

[12] Public Health Ontario, 2020, Coronavirus Disease 2019 (COVID-19): How to Protect Yourself from COVID-19 – Older Adults and People with Chronic Medical Conditions or Weakened Immune Systems. Queen’s Printer for Ontario 2020, Date of access: 14/10/2020. https://www.publichealthontario.ca/-/media/documents/ncov/factsheet/2020/05/factsheet-covid-19-immunocompromised.pdf?la=en.

[13] National Association of Chronic Disease Directors, 2020, Chronic Disease and COVID-19: What You Need to Know Tips and information to protect yourself and your family, National Association of Chronic Disease Directors 2020. Date of access: 15/10/2020. https://cdn.ymaws.com/www.chronicdisease.org/resource/resmgr/website-2020/covid/factsheet_covid19cd.pdf.

[14] Bener A., Alsaied A., Al-Ali M., Hassan A.S., Basha B., Al-Kubaisi A., et al., 2009, Impact of Lifestyle and Dietary Habits on Hypovitaminosis D in Type 1 Diabetes Mellitus and Healthy Children from Qatar, a Sun-Rich Country, Annals of Nutrition & Metabolism, 53 (3/4): 215 – 222. https://www.jstor.org/stable/48507937.

[15] Zgaga L., Theodoratou E., Farrington S.M., Agakov F., Tenesa A., Walker M., et al., 2011, Diet, Environmental Factors, and Lifestyle Underlie the High Prevalence of Vitamin D Deficiency in Healthy Adults in Scotland, and Supplementation Reduces the Proportion That Are Severely Deficient, The Journal of Nutrition, 6: 1535 – 42. doi:10.3945/jn.111.140012.

[16] Bonevski B., 2020. Does nicotine protect us against coronavirus? The Conversation Africa, Inc. 2020. Date of access: 10/09/2020. https://theconversation.com/does-nicotineprotect-us-against-coronavirus-137488.

[17] van Zyl-Smit R., Richards G., and Leone F.T., 2020, Tobacco smoking and COVID-19 infection, thelancet.com/respiratory, 8: 664 – 5.

[18] World Health Organization, 2020, WHO statement: Tobacco use and COVID-19. World Health Organization 2020. Date of access: 14/10/2020. https://www.who.int/newsroom/detail/11-05-2020-who-statement-tobacco-use-and-covid- 19.

[19] Banerjee B, and Banerjee R., 2020, Role of tobacco in SARS-CoV-2 infection and COVID-19: A scoping review. Int J Non-Commun Dis, 5:70 – 5.

[20] Yu G., 2020, How smoking, vaping and drug use might increase risks from Covid-19. CNN 2020. Date of access: 18/10/2020. https://edition.cnn.com/2020/03/20/health/coronavirus-vaping-drugs/index.html.

[21] Landsverk G., 2020, There's new evidence vitamin D may help treat COVID-19 by reducing the severity of infection. Insider Inc 2020. Date of access: 28/10/2020. https://www.insider.com/new-evidence-suggests-vitamin-d-could-reduce-coronavirus-severity-2020-10.

[22] Miller A.M., 2020, Over 80% of coronavirus patients had vitamin D deficiency in one Spanish hospital. Insider Inc 2020. Date of access: 28/10/2020. https://www.insider.com/80-percent-of-hospitalized-coronavirus-patients-had-vitamin-d-deficiency-2020-10.

[23] Nasri H., and Ardalan M.R., 2012, Association of serum vitamin D level with age in individuals with normal renal function, J Nephropharmacol, 1(1): 7–9.

[24] Roomi M.A., Farooq A., Ullah E., and Lone K.P., 2015, Hypovitaminosis D and its association with lifestyle factors, Pak J Med Sci, 31(5): 1236 – 1240. http://dx.doi.org/10.12669/pjms.315.7196.

[25] World Health Organization, 2020, Nutrition advice for adults during the COVID-19 outbreak. World Health Organization 2020. Date of access: 27/08/2020. http://www.emro.who.int/images/stories/nutrition/documents/en_flyer_nutrition_adults_covid_19.pdf?ua=1.

[26] World Health Organization, 2020, Clinical management of COVID-19: Interim guidance. WHO 2020, Date of access: 15/10/2020? https://www.who.int/publications/i/item/clinical-management-of-covid-19.

[27] Wang L., 2020, C-reactive protein levels in the early stage of COVID-19, Médecine et maladies infectieuses, 50: 332–334.

[28] Apicella M., Campopiano M.C., Mantuano M., Mazoni L., Coppelli A., and Del Prato S., 2020, COVID-19 in people with diabetes: understanding the reasons for worse outcomes. thelancet.com/diabetes-endocrinology, 8: 782 – 92.

[29] Pugliese G., Vitale M., Resi V., and Orsi E., 2020, Is diabetes mellitus a risk factor for Coronavirus Disease 19 (COVID-19)? Acta Diabetol., 31: 1 – 11. doi: 10.1007/s00592-020-01586-6.

[30] Casqueiro J., Casqueiro J., and Alves C., 2012, Infections in patients with diabetes mellitus: A review of pathogenesis, Indian Journal of Endocrinology and Metabolism, 16 (1): 27 – 36. DOI: 10.4103/2230-8210.94253.

[31] Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., et al., 2020, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases, 94: 91–95. https://doi.org/10.1016/j.ijid.2020.03.017.

[32] Guan W., Ni Z., Hu Y., Liang W., Ou C., He J. et al., 2020, Clinical Characteristics of Coronavirus Disease 2019 in China, n engl j med, 382: 1708 – 1720, DOI: 10.1056/NEJMoa2002032.

[33] Pal R., and Bhadada S.K., 2020, COVID-19 and non-communicable diseases, Postgrad Med J, 96: 429 – 430.

[34] Verma N., Duseja A., and Singh V., 2020, Impact of Pre-existing Chronic Liver Disease on the Outcome of Patients with COVID-19 Disease, Gastroenterology 2020, doi: https://doi.org/10.1053/j.gastro.2020.05.090. Date of access: 15/10/2020. https://www.gastrojournal.org/article/S0016-5085(20)34782-X/pdf.

[35] Oyelade T., Alqahtani j., and Canciani G., 2020, Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis, Trop. Med. Infect. Dis., 5 (80): 1 – 14. doi:10.3390/tropicalmed5020080.

[36] Bonita R., Beaglehole R., and Kjellström T., 2006, Basic epidemiology 2^nd edition. World Health Organization 2006. Date of access: 16/10/2020. https://apps.who.int/iris/bitstream/handle/10665/43541/9241547073_eng.pdf?sequence=1&isAllowed=y.

[37] Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., et al., 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J., 34(28): 2159-219. DOI: 10.1093/eurheartj/eht151.

[38] Cosentino F., Grant P.J., Aboyans V., Bailey

C.J., Ceriello1 A., Delgado V., et al., 2019, 2019 European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the European Association of the Study of Diabetes (EASD). European Heart Journal, 00: 1 – 69. DOI:10.1093/eurheartj/ehz486.

[39] World Health Organization, 2009, A Training Manual for Health Workers on Healthy Lifestyle: An Approach for the Prevention and Control of Non-Communicable Diseases. Date of access: 1/10/2020. http://www.wpro.who.int/philippines/publications/trainersguide.pdf.

[40] Kelly J, & Shull J., 2019, Foundations of Lifestyle Medicine: The Lifestyle Medicine Board Review Manual. 2^nd ed. (Chesterfield, MO: United States of America).

[41] United Nations, 2011, Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. United Nations 2011, Date of access: 15/10/2020. https://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_en.pdf?ua=1.

[42]Hunter C.L., Rubin H., and Kim K., 2020, COVID-19 Economic Impacts: Beware the Ides of March – A Day Romans Settled Debts, KPMG Economics 2020, Date of access: 15/10/2020. https://assets.kpmg/content/dam/kpmg/cl/pdf/2020-03-kpmg-chile-advisory-coronavirus-mapping.pdf.

[43] Alschuler L, Weil A, Horwitz R, Stamets P., Chiassona A., Crockera R., and Maizesa V., 2020, Integrative considerations during the COVID-19 pandemic, Explore, (00):1 – 3.

[44] World Health Organization, 2007, Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. Date of access: 8/10/2020. http://www.who.int/cardiovascular_diseases/guidelines/Full%20text.pdf.

[45] Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein J. H., et al., 2008, Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation, J. Am. Coll. Cardiol., 51, 1512 – 1524. DOI: 10.1016/j.jacc.2008.02.034.

[46]  University of Leicester, 2012, Updated. The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management. Date of access: 31/12/2016. https://legacyscreening.phe.org.uk/policydb_download.php?doc=259.